Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-positive cancers

Viswanath Das,Gopal Muddasani,Naveen Kumar Rampeesa,Sreenivasareddy Anugu,Pullareddy Muddasani,Soňa Gurská,Petr Džubák,Marián Hajdúch,Rambabu Gundla

DOI: https://doi.org/10.26434/chemrxiv-2024-hrfmw-v2

2024-09-13

Abstract:Bruton's tyrosine kinase (BTK) and Interleukin-2-inducible T-cell kinase (ITK) are two important members of the Tec family with crucial roles in immune system function. Deregulation in ITK and BTK activity is linked to several hematological malignancies, making them key targets for cancer immunotherapy. In this study, we synthesized new azaspirooxindolinone derivatives and evaluated their cytotoxic activity against ITK/BTK-negative and -positive cancer cell lines. Compounds 3d and 3j exhibited high cytotoxicity in both ITK-positive Jurkat (IC50 = 3.58 µM and 4.16 µM, respectively) and BTK-positive Ramos (IC50 = 3.06 µM and 1.38 µM, respectively) cell lines, indicating their potential dual activity against ITK and BTK. 3a and 3e showed high cytotoxicity specifically in ITK-positive Jurkat cells with IC50 values of 9.36 µM and 10.85 µM, respectively. Compounds 3f and 3g were highly cytotoxic specifically in Ramos cells with IC50 values of 1.82 µM and 1.42 µM, respectively. None of the active compounds exhibited cytotoxic effects against non-cancer cell lines (IC50 > 50 µM). These findings suggest that the synthesized azaspirooxindolinone derivatives, particularly compounds 3d and 3j, hold promise as dual inhibitors for ITK and BTK-positive cancers, while compounds 3a, 3e, 3f, and 3g demonstrate potential as specific inhibitors, warranting further investigation.

Chemistry

What problem does this paper attempt to address?

The paper attempts to address the problem of developing novel and efficient inhibitors in cancer immunotherapy. Specifically, the paper aims to design, synthesize, and evaluate a series of new azole spirooxazoline derivatives as inhibitors of ITK (Interleukin-2 Inducible T-cell Kinase) and BTK (Bruton's Tyrosine Kinase). These two kinases play critical roles in the function of the immune system, and their abnormal activity is associated with various hematologic malignancies. By studying the cytotoxic effects of these compounds on different cancer cell lines, the paper hopes to identify compounds with potential dual inhibitory effects (targeting ITK and BTK) and provide a basis for further drug development. Notably, compounds 3d and 3j exhibit high cytotoxicity against ITK and BTK positive cancer cells, indicating their potential as dual inhibitors. Other compounds such as 3a, 3e, 3f, and 3g show specific inhibitory effects and warrant further investigation.

Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-positive cancers

Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-positive cancers

Novel Azaspirooxindolinone-Based PROTACs for Selective BTK Degradation and Enhanced Anticancer Activity

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Expression analysis, molecular docking and molecular dynamics simulations to identify potential BTK inhibitors: strategy for targeting pan-cancer

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase

Combining structure-based pharmacophore modeling and machine learning for the identification of novel BTK inhibitors

Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy

ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas

Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with in Vivo Activity.

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.

Design and synthesis of CNX-774 analogues as BTK-related cancer inhibitors

Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas

Convenient Synthesis, Characterizations and Biological Evolution of Novel 1‐Phenyl‐N'‐(3‐phenylacryloyl)cyclopropane carbohydrazide Derivatives